

# Use of Octavius 4D for the Patient Specific Dose Validation of Single-Isocenter Multiple Brain Metastasis Stereotactic Radiosurgery

J McCulloch, J Pawlowski, N Kirby, K Rasmussen, Z Shi, P Myers, S Stathakis, N Papanikolaou, D Saenz  
UT Health San Antonio

## INTRODUCTION

The purpose of this study was to assess the ability of the PTW Octavius 4D Modular Phantom (O4D) to perform quality assurance for single-isocenter multiple brain metastasis stereotactic radiosurgery and determine what fraction of lesions are measurable on the 11 x 11 PTW 1000 SRS detector array.



Figure 1: The Octavius 4D Modular Phantom set up for SRS patient specific QA

## METHODS

The O4D is a water equivalent cylindrical phantom equipped with an insert for the 1000 SRS array. The array is composed of 977 liquid-filled ionization chambers that are spaced 2.5 mm apart in the inner 5.5 cm x 5.5 cm square and 5 mm apart in the outer 11 cm x 11 cm square. An inclinometer is placed on the gantry that allows for the O4D to rotate in synchronization with the gantry. All QA plans were delivered at a couch angle of 0 degrees.

15 SRS patient plans with multiple targets (2 – 11) created with Brainlab Elements Multiple Brain Metastases 2.0 were recalculated on the O4D and analyzed using Verisoft with a gamma criteria of 3%/1mm. Verisoft was given each beams intended table angle and a non-coplanar dose cloud was calculated. Lesions visible in the dose cloud were considered measurable.

## RESULTS

| Patient Number | Number of Targets | Number of measurable lesions | Gamma Passing Rate (3%/1mm) |
|----------------|-------------------|------------------------------|-----------------------------|
| 1              | 5                 | 4                            | 99.4%                       |
| 2              | 2                 | 2                            | 100%                        |
| 3              | 5                 | 3                            | 99.4%                       |
| 4              | 4                 | 4                            | 99.8%                       |
| 5              | 3                 | 1                            | 99.9%                       |
| 6              | 4                 | 3                            | 99.7%                       |
| 7              | 11                | 8                            | 98.9%                       |
| 8              | 10                | 9                            | 99.4%                       |
| 9              | 3                 | 3                            | 99.5%                       |
| 10             | 4                 | 3                            | 98.0%                       |
| 11             | 5                 | 5                            | 98.2%                       |
| 12             | 9                 | 8                            | 98.1%                       |
| 13             | 3                 | 3                            | 100%                        |
| 14             | 3                 | 3                            | 99.5%                       |
| 15             | 3                 | 2                            | 99.7%                       |

Table 1: Patient Demographics

| Patient Number | Number of Targets | Average CI | Average GI | Prescription Volume |
|----------------|-------------------|------------|------------|---------------------|
| 1              | 5                 | 1.31       | 3.88       | 99.5%               |
| 2              | 2                 | 1.21       | 2.93       | 99.5%               |
| 3              | 5                 | 1.37       | 5.55       | 99.5%               |
| 4              | 4                 | 1.55       | 4.12       | 99.5%               |
| 5              | 3                 | 1.31       | 3.25       | 99.5%               |
| 6              | 4                 | 1.71       | 3.93       | 99.5%               |
| 7              | 11                | 1.60       | 6.10       | 99.5%               |
| 8              | 10                | 1.63       | 6.01       | 99.5%               |
| 9              | 3                 | 1.31       | 4.47       | 99.5%               |
| 10             | 4                 | 1.39       | 4.97       | 99.5%               |
| 11             | 5                 | 1.32       | 5.32       | 99.5%               |
| 12             | 9                 | 1.61       | 6.89       | 99.5%               |
| 13             | 3                 | 1.47       | 4.75       | 99.5%               |
| 14             | 3                 | 1.33       | 3.54       | 99.5%               |
| 15             | 3                 | 1.53       | 6.53       | 99.5%               |

Table 2: Individual results for each patient



Figure 2: The Octavius 4D Modular Phantom set up for SRS patient specific QA

|                                     |       |
|-------------------------------------|-------|
| Total Number of Targets             | 74    |
| Total Number of Measurable Targets  | 61    |
| Average Gamma Passing Rate (3%/1mm) | 99.3% |

Table 3: Summary of results

There were 74 targets amongst the 15 patients. 61 of these targets were visible in the measured dose clouds (82%). The average gamma passing rate was 99.3% with a sample standard deviation of 0.68%.




Figure 3: Measured Dose from a single slice of the O4D phantom. The Dash lines show the calculated plan and the solid lines show the measured plan




Figure 4: Measured dose profile (blue) vs calculated dose profile (orange)

## CONCLUSIONS

The O4D is of a large enough size that a majority of targets can be QA'd for single-isocenter multiple brain metastasis stereotactic radiosurgery. The close detector spacing allows for very high resolution sufficient for patient-specific dose verification.

## CONTACT INFORMATION

mccullochja@livemail.uthscsa.edu